← Back to Precision Drilling Stock
Precision Drilling (PD.TO) News
Eric Nuttall, partner and senior portfolio manager at Ninepoint Partners, discusses his top picks: Baytex Energy, Nuvista Energy, and Precision Drilling.
Precision Drilling (TSE:PD) has released an update. Precision Drilling Corporation has announced an extension of its Senior Credit Facility to 2027…
Precision Drilling Corporation is experiencing growth in service rigs, driven by Trans Mountain pipeline expansion and regulatory spending requirements, potentially accelerating demand for the stock. Recent plans to reduce debt levels and distribute 25%-35% of FCF to shareholders could further boost stock demand. The business review highlights drilling as the most relevant activity, with potential synergies from CWC Energy Services acquisition and automation technologies enhancing future drilling activities.
Precision Drilling (TSE:PD) has released an update. Precision Drilling Corporation is slated to release its second quarter results for 2024 after m…
CALGARY, Alberta, July 03, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2024 second quarter results after the market closes on Tuesday, July 30, 2024, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Wednesday, July 31, 2024.
PagerDuty (NYSE: PD ) just reported results for the first quarter of 2025. PagerDuty reported earnings per share of 17 cents. This was above the analyst estimate for EPS of 13 cents. The company reported revenue of $111.17 million. This was 0.25% worse than the analyst estimate for revenue of $111.45 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I.
The company will present the results of two clinical trials that expand the potential health impact of its flagship 24-strain probiotic and prebiotic, DS-01® BOSTON, May 20, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two randomized, double-blind, placebo-controlled clinical trials: one assessing the recovery effects of DS-01® on individuals during and following antibiotic usage, and another evaluating DS-01® in patients with irritable bowel syndrome (IBS). The findings underscore Seed's mission to transform breakthrough microbiome science into clinically validated consumer health innovations. "DS-01® was formulated to maximize genomic diversity and set an entirely new standard in probiotics," stated Zain Kassam, M.D., M.P.H, Chief Medical Officer at Seed Health. "Our latest clinical data expands DS-01®'s potential health impact, broadens its clinical use cases, and helps dispel the common perception in the medical community that all probiotics are created equal." Dirk Gevers, Ph.D., Chief Scientific Officer at Seed Health, added, "The findings presented at DDW highlight the rigorous biopharma approach we bring to everyday health. We evaluated digestive well-being by studying biopharmaceutical-type biomarkers, exploring possible mechanisms of action in IBS, and conducting deeper microbiome sequencing than typical probiotic trials following antibiotics." DDW Presentation Highlights These presentations will detail the methodology and results from the two clinical trials which have important implications for the application of microbiome science in consumer health and well-being. Seed's Health clinical data on DS-01® Daily Synbiotic for antibiotic recovery and IBS will be presented in the session "Prebiotics, Probiotics and Synbiotics in Health and Disease" on May 20, 2024, from 12:30 PM to 1:30 PM EDT. About Seed HealthSeed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health. Founded to realize the potential of the microbiome, our platform enables the translation of breakthrough science across a portfolio targeting health outcomes from infancy to aging. Our consumer innovations are commercialized under Seed®, an award-winning, science-first brand known for clinically validated innovations in probiotics, including DS-01® Daily Synbiotic and PDS-08® Pediatric Daily Synbiotic. Our pipeline encompasses both indication-specific and preventive applications for gastrointestinal and digestive health, women's health, skin, pediatrics, brain health, metabolic function, and healthy aging. Our environmental research is conducted under SeedLabs, which was founded to advance novel bacterial interventions to enhance biodiversity and restore ecosystems impacted by human activity. Media Contact[email protected]
Precision Drilling Corp (TSE:PD) has released an update. Precision Drilling Corporation reported successful election results for its board members …
Precision Drilling Corp (TSE:PD) has released an update. Precision Drilling Corporation announces successful election of board members at the 2024 …
CALGARY, Alberta, May 16, 2024 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) is pleased to announce the results of the election of board members at its 2024 Annual and Special Meeting of Shareholders held on May 16, 2024 (the Annual Meeting). Shareholders approved the election of all eight (seven of whom are independent) of the nominee directors presented in the Company's Management Information Circular (the Circular), dated April 3, 2024.